KR20240053656A - 인간 모노카르복실레이트 수송체 1 항체 및 그의 용도 - Google Patents

인간 모노카르복실레이트 수송체 1 항체 및 그의 용도 Download PDF

Info

Publication number
KR20240053656A
KR20240053656A KR1020247011816A KR20247011816A KR20240053656A KR 20240053656 A KR20240053656 A KR 20240053656A KR 1020247011816 A KR1020247011816 A KR 1020247011816A KR 20247011816 A KR20247011816 A KR 20247011816A KR 20240053656 A KR20240053656 A KR 20240053656A
Authority
KR
South Korea
Prior art keywords
seq
antibody
includes seq
nucleic acid
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247011816A
Other languages
English (en)
Korean (ko)
Inventor
프랭크 찰스 돌시
조셉 벤자민 그레인저
키라 블라디미로브나 룹트소바
올리버 슈뢰더
웨이 왕
Original Assignee
이뮤노메타볼리즘 디벨롭먼트 컴퍼니, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노메타볼리즘 디벨롭먼트 컴퍼니, 엘엘씨 filed Critical 이뮤노메타볼리즘 디벨롭먼트 컴퍼니, 엘엘씨
Publication of KR20240053656A publication Critical patent/KR20240053656A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247011816A 2021-09-14 2022-09-14 인간 모노카르복실레이트 수송체 1 항체 및 그의 용도 Pending KR20240053656A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163261177P 2021-09-14 2021-09-14
US63/261,177 2021-09-14
US202163272903P 2021-10-28 2021-10-28
US63/272,903 2021-10-28
PCT/US2022/076400 WO2023044325A1 (en) 2021-09-14 2022-09-14 Human monocarboxylate transporter 1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20240053656A true KR20240053656A (ko) 2024-04-24

Family

ID=83558178

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247011816A Pending KR20240053656A (ko) 2021-09-14 2022-09-14 인간 모노카르복실레이트 수송체 1 항체 및 그의 용도

Country Status (16)

Country Link
US (1) US11987624B2 (enExample)
EP (1) EP4402172A1 (enExample)
JP (2) JP7753348B2 (enExample)
KR (1) KR20240053656A (enExample)
AU (1) AU2022347031B2 (enExample)
CA (1) CA3230072A1 (enExample)
CL (1) CL2024000733A1 (enExample)
CO (1) CO2024003042A2 (enExample)
CR (1) CR20240133A (enExample)
DO (1) DOP2024000049A (enExample)
EC (1) ECSP24020235A (enExample)
IL (1) IL311253A (enExample)
JO (1) JOP20240054A1 (enExample)
MX (1) MX2024003115A (enExample)
TW (1) TWI842088B (enExample)
WO (1) WO2023044325A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087259A1 (en) 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132813A1 (en) 2001-05-30 2004-07-08 Brooks George A. Glycerol-lactate esters for use as an energy supplement during exercise and recovery
WO2012178173A1 (en) 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
GB201418626D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Method
CA3087259A1 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Also Published As

Publication number Publication date
TWI842088B (zh) 2024-05-11
WO2023044325A1 (en) 2023-03-23
CR20240133A (es) 2024-05-06
MX2024003115A (es) 2024-06-19
CL2024000733A1 (es) 2024-08-30
IL311253A (en) 2024-05-01
JP7753348B2 (ja) 2025-10-14
AU2022347031B2 (en) 2026-07-23
TW202330602A (zh) 2023-08-01
CA3230072A1 (en) 2023-03-23
DOP2024000049A (es) 2024-06-16
JP2026004435A (ja) 2026-01-14
WO2023044325A9 (en) 2024-04-25
ECSP24020235A (es) 2024-06-28
CO2024003042A2 (es) 2024-03-18
JOP20240054A1 (ar) 2024-03-13
JP2023542639A (ja) 2023-10-11
US20230111363A1 (en) 2023-04-13
AU2022347031A1 (en) 2024-03-14
US11987624B2 (en) 2024-05-21
EP4402172A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US20230340155A1 (en) Antibodies that Specifically Bind PD-1 and Methods of Use
US20220380479A1 (en) Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
EP3172233B1 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
US20240228615A1 (en) Anti-trem-1 antibodies and uses thereof
CN117545779B (zh) 抗ctla-4抗体的用途
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
JP2022058414A (ja) 抗ｃｄ１５４抗体及びこれを使用する方法
AU2018344417A1 (en) CD3/CD33 bispecific binding molecules
WO2021207827A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
JP2026004435A (ja) ヒトモノカルボン酸トランスポーター１抗体及びその使用
CN118043353A (zh) 人单羧酸转运蛋白1抗体及其用途
EA049820B1 (ru) Антитела к btla
EA046142B1 (ru) Антитела к trem-1 и их применения
EA040943B1 (ru) Антитела к cd154 и способы их применения

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902